Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination

Fagni F, Schmidt K, Bohr D, Valor-Mendez L, Tascilar K, Manger K, Manger B, Kleyer A, Simon D, Schett G, Harrer T, Hartmann F (2022)

Publication Type: Journal article, Letter

Publication year: 2022

Journal

RMD Open BMJ Publishing Group

Book Volume: 8

Article Number: e002323

Journal Issue: 1

DOI: 10.1136/rmdopen-2022-002323

Authors with CRIS profile

Filippo Fagni Department of Medicine 3 – Rheumatology and Immunology Koray Tascilar Department of Medicine 3 – Rheumatology and Immunology Bernhard Manger Professur für Rheumatologie und Klinische Immunologie Arnd Kleyer Department of Medicine 3 – Rheumatology and Immunology David Simon Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III Thomas Harrer Professur für Innere Medizin mit dem Schwerpunkt Immundefizienz

How to cite

APA:

Fagni, F., Schmidt, K., Bohr, D., Valor-Mendez, L., Tascilar, K., Manger, K.,... Hartmann, F. (2022). Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination. RMD Open, 8(1). https://doi.org/10.1136/rmdopen-2022-002323

MLA:

Fagni, Filippo, et al. "Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination." RMD Open 8.1 (2022).

BibTeX: Download